Mezagitamab not checked

Takeda · TAK-079

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
11 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Immune Thrombocytopenic Purpura (ITP) (2 trials), Kidney Disease, Antibody-Mediated Rejection (AMR)
Main trialPhase 3
“Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the…”In the company’s words, NCT06722235 on ClinicalTrials.gov
Other names
TAK-079

Other drugs for Immune Thrombocytopenic Purpura (ITP)

All 32 drugs for Immune Thrombocytopenic Purpura (ITP)

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 16 Mar 2028 A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Phase 3Recruiting 7 Sep 2028 A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Phase 3Recruiting 29 Jul 2029 A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Phase 2Recruiting 15 Jan 2029 A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Phase 2Completed 12 Jul 2022 A Study of TAK-079 in People With Generalized Myasthenia Gravis
Phase 2Completed 29 Apr 2024 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Phase 1/2Completed 28 Jan 2022 A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Phase 1/2Terminated 2 Aug 2023 A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1Completed 4 Nov 2021 A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Phase 1Completed 15 Dec 2025 A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
Phase 1Completed 25 Mar 2026 A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mezagitamab

Following is part of Solo: you see every change to Mezagitamab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in